Jianxin You

Dr. Jianxin You

Department of Microbiology University of Pennsylvania Perelman School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2018 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
NKNathan A. Krump
Nathan A. Krump
Jianxin YouJianxin You
Jianxin You

1 June 2016 in Cell Host & Microbe
Verified
Journal Article
Closed access
WLWei Liu
Wei Liu
RYRuifeng Yang
Ruifeng Yang
APAimee S. Payne
Aimee S. Payne
RSRachel M. Schowalter
Rachel M. Schowalter
MSMegan E. Spurgeon
Megan E. Spurgeon
Jianxin YouJianxin You
Jianxin You

18 August 2017 in Viruses
Verified
Journal Article
Open access
PDF file
SSSrinidhi Shanmugasundaram
Srinidhi Shanmugasundaram
Jianxin YouJianxin You
Jianxin You
While the majority of Human papillomavirus (HPV) infections are transient and cleared within a couple of years following exposure, 10–20% of infections persist latently, leading to disease progression and, ultimately, various forms of invasive cancer. Despite the clinical efficiency of recently developed multivalent prophylactic HPV vaccines, these preventive measures are not effective against pre-existing infection. Additionally, considering that the burden associated with HPV is greatest in regions with limited access to preventative vaccination, the development of effective therapies targeting persistent infection remains imperative. This review discusses not only the mechanisms underlying persistent HPV infection, but also the promise of immunomodulatory therapeutic vaccines and small-molecular inhibitors, which aim to augment the host immune response against the viral infection as well as obstruct critical viral–host interactions.

1 March 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RWRanran Wang
Ranran Wang
QLQing Li
Qing Li
CHChristine M. Helfer
Christine M. Helfer
JJJing Jiao
Jing Jiao
Jianxin YouJianxin You
Jianxin You
Chromatin structure organization is crucial for regulating many fundamental cellular processes. However, the molecular mechanism that regulates the assembly of higher-order chromatin structure remains poorly understood. In this study, we demonstrate that Brd4 (bromodomain-containing protein 4) protein participates in the maintenance of the higher-order chromatin structure. Brd4, a member of the BET family of proteins, has been shown to play important roles in cellular growth control, cell cycle progression, and cancer development. We apply in situ single cell chromatin imaging and micrococcal nuclease (MNase) assay to show that Brd4 depletion leads to a large scale chromatin unfolding. A dominant-negative inhibitor encoding the double bromodomains (BDI/II) of Brd4 can competitively dissociate endogenous Brd4 from chromatin to trigger severely fragmented chromatin morphology. Mechanistic studies using Brd4 truncation mutants reveal that the Brd4 C-terminal domain is crucial for maintaining normal chromatin structure. Using bimolecular fluorescence complementation technology, we demonstrate that Brd4 molecules interact intermolecularly on chromatin and that replacing Brd4 molecules by BDI/II causes abnormal nucleosome aggregation and chromatin fragmentation. These studies establish a novel structural role of Brd4 in supporting the higher chromatin architecture.

15 August 2013 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
JLJing Li
Jing Li
XWXin Wang
Xin Wang
JDJason Diaz
Jason Diaz
STSabrina H. Tsang
Sabrina H. Tsang
CBChristopher B. Buck
Christopher B. Buck
Jianxin YouJianxin You
Jianxin You
Clonal integration of Merkel cell polyomavirus (MCV) DNA into the host genome has been observed in at least 80% of Merkel cell carcinoma (MCC). The integrated viral genome typically carries mutations that truncate the C-terminal DNA binding and helicase domains of the MCV large T antigen (LT), suggesting a selective pressure to remove this MCV LT region during tumor development. In this study, we show that MCV infection leads to the activation of host DNA damage responses (DDR). This activity was mapped to the C-terminal helicase-containing region of the MCV LT. The MCV LT-activated DNA damage kinases, in turn, led to enhanced p53 phosphorylation, upregulation of p53 downstream target genes, and cell cycle arrest. Compared to the N-terminal MCV LT fragment that is usually preserved in mutants isolated from MCC tumors, full-length MCV LT shows a decreased potential to support cellular proliferation, focus formation, and anchorage-independent cell growth. These apparently antitumorigenic effects can be reversed by a dominant-negative p53 inhibitor. Our results demonstrate that MCV LT-induced DDR activates p53 pathway, leading to the inhibition of cellular proliferation. This study reveals a key difference between MCV LT and simian vacuolating virus 40 LT, which activates a DDR but inhibits p53 function. This study also explains, in part, why truncation mutations that remove the MCV LT C-terminal region are necessary for the oncogenic progression of MCV-associated cancers.

1 October 2016 in Current Opinion in Virology
Verified
Journal Article
Closed access
WLWei Liu
Wei Liu
MMMargo MacDonald
Margo MacDonald
Jianxin YouJianxin You
Jianxin You